Alnylam Makes Entry Into Chinese RNAi Market
This article was originally published in PharmAsia News
Executive Summary
Chinese small interfering siRNA supplier Shangahi GenePharma has acquired a nonexclusive worldwide license to Alnylam Pharmaceuticals' Kreutzer-Limmer patent group, which is the first business transaction in China made by the Cambridge, Mass.-based RNAi firm